학술논문
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
Document Type
article
Author
François Bertucci; Charlotte Rypens; Pascal Finetti; Arnaud Guille; José Adélaïde; Audrey Monneur; Nadine Carbuccia; Séverine Garnier; Piet Dirix; Anthony Gonçalves; Peter Vermeulen; Bisrat G. Debeb; Xiaoping Wang; Luc Dirix; Naoto T. Ueno; Patrice Viens; Massimo Cristofanilli; Max Chaffanet; Daniel Birnbaum; Steven Van Laere
Source
Molecular Oncology, Vol 14, Iss 3, Pp 504-519 (2020)
Subject
Language
English
ISSN
1878-0261
1574-7891
1574-7891
Abstract
Inflammatory breast cancer (IBC) is the most pro‐metastatic form of breast cancer. Better understanding of its pathophysiology and identification of actionable genetic alterations (AGAs) are crucial to improve systemic treatment. We aimed to define the DNA profiles of IBC vs noninflammatory breast cancer (non‐IBC) clinical samples in terms of copy number alterations (CNAs), mutations, and AGAs. We applied targeted next‐generation sequencing (tNGS) and array‐comparative genomic hybridization (aCGH) to 57 IBC and 50 non‐IBC samples and pooled these data with four public datasets profiled using NGS and aCGH, leading to a total of 101 IBC and 2351 non‐IBC untreated primary tumors. The respective percentages of each molecular subtype [hormone receptor‐positive (HR+)/HER2−, HER2+, and triple‐negative] were 68%, 15%, and 17% in non‐IBC vs 25%, 35%, and 40% in IBC. The comparisons were adjusted for both the molecular subtypes and the American Joint Committee on Cancer (AJCC) stage. The 10 most frequently altered genes in IBCs were TP53 (63%), HER2/ERBB2 (30%), MYC (27%), PIK3CA (21%), BRCA2 (14%), CCND1 (13%), GATA3 (13%), NOTCH1 (12%), FGFR1 (11%), and ARID1A (10%). The tumor mutational burden was higher in IBC than in non‐IBC. We identified 96 genes with an alteration frequency (p